AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Increased access to high-quality mammography needed to reduce cancer deaths.

Women's Health Weekly

| July 01, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 JUL 1 - (NewsRx.com & NewsRx.net) -- While new technologies hold promise for increasing the accuracy of breast cancer detection, improving access to mammography and broadening the pool of medical personnel who can interpret mammograms offer the greatest potential for immediately reducing the number of lives lost to breast cancer in the United States, says a new report released June 10, 2004, by the Institute of Medicine (IOM) and National Research Council (NRC) of the National Academies.

"There is a suite of new devices under evaluation, such as ultrasound and computer-aided detection (CAD), that should make early detection even more effective in the future, although improvements in the next few years are likely to be incremental rather than revolutionary," said committee chair Edward Penhoet, director of science and higher education programs, Gordon and Betty Moore Foundation, San Francisco, and former dean, School of Public Health, University of California, Berkeley.

New technologies based on protein or gene profiling hold promise for providing more personalized screenings and identifying women at greatest risk for breast cancer. It remains to be shown, however, whether these technologies will yield results that are reliable enough to be useful in the early detection of breast cancer, said the committee that wrote the report.

"In the meantime, because current mammography technology is good but imperfect, and because there are many barriers hindering access to mammography, too many women will die from breast cancer [in 2004]," Penhoet said. "Improving and increasing the use of current mammography technology is the most effective strategy we have right now for further reducing the toll of breast cancer."

One of the biggest problems facing women today is that their access to breast cancer screening is endangered due to a shortage of breast imaging specialists, the report says. Each year, more than 1.2 million American women turn 40, the age when most are recommended to get their first mammogram, but there are not enough breast imaging specialists to keep up with the demand.

Fewer radiologists are going into breast imaging because of heavy regulation, fear of lawsuits, and low reimbursement for long hours. At the same time, mammography facilities are closing faster than new ones are opening. Between 2000 and 2003, the number of mammography facilities operating in the United States has dropped from 9,400 to 8,600 - an 8.5% decrease. As a result, women are being made to wait up to 5 months for mammograms in some areas, the report notes.

Studies in the United Kingdom show that trained, nonphysician, healthcare professionals can interpret results with the same accuracy and speed as radiologists. Given the failure of the U.S. healthcare system to keep pace with the growing demand for mammography, the committee recommended that mammography facilities should enlist specially trained nonphysician personnel to pre-screen or double-read mammograms to expand screening facilities' capacity. Nonphysician personnel would not make diagnoses, and every mammogram would be independently viewed by a breast-imaging specialist.

Related articles from newspapers, magazines, journals, and more
NEW ANTI-CANCER AGENT, TAXOTERE(R) (docetaxel), NOW AVAILABLE TO TREAT ADVANCED...
Press release article from: PR Newswire January 24, 1996 700+ words
...treatment of advanced breast cancer, is now available in the United Kingdom, where it may benefit...patients with advanced breast cancer who have failed...available." The United Kingdom has one of the highest breast cancer death rates in the...
Genomic Health Announces Exclusive Distribution Agreement for Oncotype DX...
Press release article from: PR Newswire June 1, 2007 700+ words
...company's Oncotype DX breast cancer assay in the United Kingdom. "We view this U.K...making our Oncotype DX breast cancer assay more widely available...predict the likelihood of breast cancer recurrence and the likelihood...
Celsion's Investigational Breast Cancer Treatment System Granted Medical Device...
Press release article from: PR Newswire January 11, 2001 700+ words
...government of the United Kingdom, has granted the...s investigational breast cancer treatment system medical...use of Celsion's breast cancer treatment system in...s investigational breast cancer treatment system...
Agendia Announces a Distribution Agreement With Opaldia to Introduce its...
Press release article from: PR Newswire Europe March 30, 2006 700+ words
...R) in the United Kingdom. MammaPrint...to classify breast cancer patients as...can also get breast cancer but it is rare...tests in the United Kingdom, opening the...assessment of breast cancer recurrence...
Rapid diagnosis while you wait. (Breast Cancer).(device being developed at...
Magazine article from: Chemistry and Industry June 17, 2002 700+ words
A device that can diagnose breast cancer within minutes is being developed by scientists at the University of Dundee, UK. The device, which is based on ultrasound...
Bioenvision Announces New Breast Cancer Studies with Modrenal.
Press release article from: Business Wire December 5, 2003 700+ words
...post-menopausal breast cancer by United Kingdom regulatory authorities...700 patients with breast cancer have received Modrenal...marketing in the United Kingdom for the treatment...post-menopausal breast cancer following relapse...
New Data Underlines Modrenal's Genetic Mechanism of Action in Breast Cancer.
Press release article from: Business Wire December 5, 2003 700+ words
...Statistics from Breast Cancer Care. About Modrenal...post-menopausal breast cancer by United Kingdom regulatory authorities...marketing in the United Kingdom for the treatment...post-menopausal breast cancer following relapse...
Bioenvision Files Investigational New Drug Application to Test Modrenal in...
Press release article from: Business Wire February 18, 2004 700+ words
...approved in the United Kingdom for the treatment...menopausal breast cancer and was commercially...menopausal breast cancer by United Kingdom regulatory...marketing in the United Kingdom for the treatment...menopausal breast cancer ...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA